TENOSYNOVIAL GIANT CELL TUMOR
Clinical trials for TENOSYNOVIAL GIANT CELL TUMOR explained in plain language.
Never miss a new study
Get alerted when new TENOSYNOVIAL GIANT CELL TUMOR trials appear
Sign up with your email to follow new studies for TENOSYNOVIAL GIANT CELL TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial offers hope for patients with rare, painful joint tumors
Disease control OngoingThis study is testing whether the drug pexidartinib can shrink tumors and improve joint movement in adults with a rare, non-cancerous joint tumor called tenosynovial giant cell tumor (TGCT). The trial is for people whose condition causes severe pain or limits their movement and c…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE3 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial targets rare, painful joint tumors
Disease control OngoingThis study is testing an oral drug called ABSK021 for adults with a rare, non-cancerous joint tumor called TGCT that cannot be fully removed by surgery. The main goal is to see if the drug shrinks tumors and improves symptoms like pain and stiffness compared to a placebo. About 9…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE3 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Experimental drug tested for rare, painful joint tumors
Disease control OngoingThis study is testing whether the drug pexidartinib is safe and effective for adults in Japan with a rare, non-cancerous joint tumor called tenosynovial giant cell tumor (TGCT). The trial is for people whose symptoms are severe and cannot be improved with surgery. Researchers wil…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE2 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug trial targets rare joint tumor and advanced cancers
Disease control OngoingThis study is testing an experimental drug called vimseltinib in adults with advanced solid tumors or a rare joint tumor called tenosynovial giant cell tumor (TGCT). The first phase aims to find the safest and most effective dose. The second phase will focus on TGCT patients to s…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New drug trial offers hope for inoperable joint tumors
Disease control OngoingThis study is testing whether an experimental drug called vimseltinib can shrink tumors in people with tenosynovial giant cell tumor (TGCT) when surgical removal isn't an option. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, wit…
Matched conditions: TENOSYNOVIAL GIANT CELL TUMOR
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC